PDF(1538 KB)
Change of serum levels of pentraxin-3 and syndecan-4 in children with chronic heart failure
ZHANG Feng-Hua, ZHAO Xiao-Lin, FENG Song, AN Jin-Dou
Chinese Journal of Contemporary Pediatrics ›› 2021, Vol. 23 ›› Issue (5) : 513-518.
PDF(1538 KB)
PDF(1538 KB)
Change of serum levels of pentraxin-3 and syndecan-4 in children with chronic heart failure
Objective To study the change and significance of serum pentraxin-3 (PTX-3) and syndecan-4 in children with chronic heart failure (CHF). Methods A total of 40 children with CHF who were admitted to the Department of Pediatrics of the First Affiliated Hospital of Zhengzhou University were enrolled as the heart failure group, and 30 children who underwent physical examination in the outpatient service during the same period of time were enrolled as the control group. The serum levels of PTX-3, syndecan-4, and N-terminal pro-brain natriuretic peptide (NT-proBNP) were compared between the two groups. Results The children with CHF had significant reductions in the serum levels of PTX-3, syndecan-4, and NT-proBNP after treatment. The levels of these markers in children with CHF were significantly higher than the control group before and after treatment (P < 0.05). The CHF children with grade II/III/IV cardiac function had significantly higher serum levels of PTX-3 and syndecan-4 than the control group (P < 0.05). The levels of PTX-3 and syndecan-4 were related to the severity of cardiac function. Compared with the grade II cardiac function group, the grade IV cardiac function group had significant increases in the serum levels of PTX-3 and syndecan-4 (P < 0.05). The serum level of PTX-3 was positively correlated with that of syndecan-4 in children with CHF (rs=0.999, P < 0.05); the serum level of PTX-3 was positively correlated with NT-proBNP, left ventricular mass index (LVMI), and cardiac function grade (rs=0.726, 0.736, and 0.934 respectively, P < 0.05) and was negatively correlated with left ventricular ejection fraction (LVEF) and left ventricular fractional shortening (LVFS) (rs=-0.852 and -0.767 respectively, P < 0.05); the serum level of syndecan-4 was positively correlated with NT-proBNP, LVMI, and cardiac function grade (rs=0.733, 0.743, and 0.934 respectively, P < 0.05) and was negatively correlated with LVEF and LVFS (rs=-0.856 and -0.771 respectively, P < 0.05). Conclusions Serum PTX-3 and syndecan-4 may be involved in the development and progression of ventricular remodeling in children with CHF and may be used as markers for the diagnosis, cardiac function grading, and treatment outcome evaluation of children with heart failure.
[1] 中华医学会心血管病学分会, 中华心血管病杂志编辑委员会. 慢性心力衰竭诊断治疗指南[J]. 中华心血管病杂志, 2007, 35(12):1076-1095.
[2] Hopper I, Easton K. Chronic heart failure[J]. Aust Prescr, 2017, 40(4):128-136.
[3] 钱明阳, 洪钿. 儿童心力衰竭的诊断与治疗进展[J]. 中华实用儿科临床杂志, 2020, 35(1):14-18.
[4] Ueland T, Gullestad L, Nymo SH, et al. Inflammatory cytokines as biomarkers in heart failure[J]. Clin Chim Acta, 2015, 443:71-77.
[5] Liu BH, Li YG, Liu JX, et al. Assessing inflammation in Chinese subjects with subtypes of heart failure:an observational study of the Chinese PLA Hospital Heart Failure Registry[J]. J Geriatr Cardiol, 2019, 16(4):313-319.
[6] Herum KM, Lunde IG, Skrbic B, et al. Syndecan-4 is a key determinant of collagen cross-linking and passive myocardial stiffness in the pressure-overloaded heart[J]. Cardiovasc Res, 2015, 106(2):217-226.
[7] 中华医学会儿科学分会心血管学组, 《中华儿科杂志》编辑委员会. 小儿心力衰竭诊断与治疗建议[J]. 中华儿科杂志, 2006, 44(10):753-757.
[8] 陈树宝. 小儿心力衰竭的诊断与治疗[J]. 中国医刊, 2008, 43(8):13-17.
[9] Ristagno G, Fumagalli F, Bottazzi B, et al. Pentraxin 3 in cardiovascular disease[J]. Front Immunol, 2019, 10:823.
[10] Farini A, Villa C, Di Silvestre D, et al. PTX3 predicts myocardial damage and fibrosis in Duchenne muscular dystrophy[J]. Front Physiol, 2020, 11:403.
[11] 孙宏超, 金凤表, 侯维娜, 等. 血清Galectin-3、PTX-3与扩张型心肌病心力衰竭临床指标的相关性[J]. 中国老年学杂志, 2020, 40(5):912-916.
[12] 贾晨红, 哈生林, 姜金坪, 等. 慢性心力衰竭患者血清Galectin-3、hs-cTnT、Cys C和PTX-3水平变化及临床意义[J]. 现代生物医学进展, 2020, 20(14):2672-2675.
[13] 康霞艳, 祝益民, 张新萍. 正五聚体蛋白3对脓毒症患儿病情及心血管功能损害的诊断价值[J]. 中华儿科杂志, 2015, 53(8):592-598.
[14] Matsubara J, Sugiyama S, Nozaki T, et al. Incremental prognostic significance of the elevated levels of pentraxin 3 in patients with heart failure with normal left ventricular ejection fraction[J]. J Am Heart Assoc, 2014, 3(4):e000928.
[15] Michel JB. Anoikis in the cardiovascular system:known and unknown extracellular mediators[J]. Arterioscler Thromb Vasc Biol, 2003, 23(12):2146-2154.
[16] Russo I, Cavalera M, Huang SB, et al. Protective effects of activated myofibroblasts in the pressure-overloaded myocardium are mediated through smad-dependent activation of a matrix-preserving program[J]. Circ Res, 2019, 124(8):1214-1227.
[17] Lunde IG, Herum KM, Carlson CC, et al. Syndecans in heart fibrosis[J]. Cell Tissue Res, 2016, 365(3):539-552.
[18] Lipphardt M, Dihazi H, Maas JH, et al. Syndecan-4 as a marker of endothelial dysfunction in patients with resistant hypertension[J]. J Clin Med, 2020, 9(9):3051.
[19] Herum KM, Romaine A, Wang A, et al. Syndecan-4 protects the heart from the profibrotic effects of thrombin-cleaved osteopontin[J]. J Am Heart Assoc, 2020, 9(3):e013518.
[20] Linssen PBC, Brunner-La Rocca HP, Schalkwijk CG, et al. Serum matrix metalloproteinases and left atrial remodeling-the hoorn study[J]. Int J Mol Sci, 2020, 21(14):4944.
[21] Takahashi R, Negishi K, Watanabe A, et al. Serum syndecan-4 is a novel biomarker for patients with chronic heart failure[J]. J Cardiol, 2011, 57(3):325-332.
